Evidence map›Paper›PMID 31632462›Full record

ArticleTherapeutic advances in urology

Oct-4: a prognostic biomarker of urinary bladder cancer in North India.

Zainab Siddiqui, Anand N Srivastava, Satya N Sankhwar, Noorin Zaidi, Naseem Fatima, Shivangi Singh, Mohd Yusuf

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zainab SiddiquiDepartment of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, India; Department of Biotechnology, Dr. A. P. J. Abdul Kalam Technical University, Lucknow, India.
Anand N SrivastavaDepartment of Pathology, Era's Lucknow Medical College and Hospital, Era University, Sarfarazganj, Lucknow-226003, Uttar Pradesh, India.ORCID https://orcid.org/0000-0001-9633-9903
Satya N SankhwarDepartment of Urology, King George's Medical University, Lucknow, India.
Noorin ZaidiDepartment of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, India.
Naseem FatimaDepartment of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, India.
Shivangi SinghResearch Metabolic Unit, Era's Lucknow Medical College and Hospital, Era University, Lucknow, India.
Mohd YusufDepartment of Pathology, King George's Medical University, Lucknow, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe objective of this study was to evaluate Octamer-binding transcription factor 4 (Oct-4), neutrophil to lymphocyte ratio (NLR) and body mass index (BMI) as independent prognostic biomarkers for prediction of urinary bladder cancer (UBC) outcomes. With the advancement in prognostic biomarker discovery, tumor recurrence is difficult to accurately predict in UBC. UBC is costly to treat due to the requirement of frequent invasive follow-up sessions. Therefore, it is of utmost importance to evaluate good prognostic biomarkers for UBC surveillance.

methodsWe studied 39 UBC tissue samples. Oct-4 protein expression was evaluated semiquantitatively by immunohistochemistry (IHC). Complete blood count data and body weight as well as the height of the patients were retrieved and recorded before the date of the first transurethral resection of bladder tumor (TURBT). The follow-up period was 48 months for recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS).

resultsOct-4 expression profile was found to be significantly associated with gender (

conclusionsWe conclude that the expression profile of Oct-4 will be beneficial in prediction of UBC recurrence, and could have profound implications on the development of new therapeutic targets for UBC treatment.

Indexed as

body mass indexcancer stem cellslymphocytesneutrophilsOct-4tumor progressiontumor recurrenceurinary bladder cancer

Identifiers

PMID31632462
PMCPMC6769204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.